Abstract
The field of autoimmune neurological disorders is rapidly expanding, and novel autoantibodies and their neuronal antigens continue to be discovered. Autoimmunity targeting brain proteins is enigmatic, because traditionally, the central nervous system (CNS) is viewed as immune-privileged. However, the discovery of the lymphatic and glymphatic circulation in the CNS demonstrates the interaction between the CNS and the immune response. Furthermore, the barriers protecting the brain from direct exposure to the immune response can be compromised by inflammations, infection, or injury. A compromised blood–brain barrier, or blood–cerebrospinal fluid barrier, will allow egress of neuronal antigens to regional and peripheral lymphoid organs and may lead to the initiation of an autoimmune response. Peripheral autoantibodies or intrathecally produced autoantibodies can reenter the CNS. Besides being useful diagnostic markers, these autoantibodies may be involved in the pathogenesis of the disease by mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and modulation of receptor function. The effect of a neural autoantibody depends not only on the nature of its antigen but also on the antibody’s Ig isotype or IgG subclass. We will discuss different causes of neurological autoimmunity and pathogenic mechanisms involved in neurological autoimmune diseases. Finally, we will discuss naturally occurring IgM autoantibodies and IgG4 autoantibodies with protective and reparative functions and appropriate treatment options.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AChR:
-
Acetylcholine receptor
- ADCC:
-
Antibody-dependent cell-mediated cytotoxicity
- AEBP1:
-
Adipocyte enhancer-binding protein-1
- AMPAR:
-
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic glutamate receptor
- AQP4:
-
Aquaporin-4
- ASD:
-
Autism spectrum disorder
- BBB:
-
Blood–brain barrier
- CA:
-
Cerebellar ataxia caspr: contactin-associated protein 1
- CDC:
-
Complement-dependent cell death
- CDR2L:
-
Cerebellar degeneration-related protein 2-like
- CIDP:
-
Chronic inflammatory demyelinating polyneuropathy
- CNS:
-
Central nervous system
- CRMP:
-
Collapsing response mediator protein
- CSF:
-
Cerebrospinal fluid
- GABA:
-
Gamma-aminobutyric acid
- GAD65:
-
65kda isoform of glutamate decarboxylase
- GBS:
-
Guillain–Barré syndrome
- GFAP:
-
Glial fibrillary acidic protein
- hnRNP-A1:
-
Heterogeneous nuclear ribonuclear protein-A1
- HSV-1:
-
Herpes simplex virus-1
- HSVE:
-
HSV encephalitis
- LDH:
-
Lactate dehydrogenase
- LEMS:
-
Lambert–Eaton myasthenic syndrome
- LRP4:
-
Lipoprotein receptor-related protein 4
- MAC:
-
Membrane attack complex
- MAG:
-
Myelin-associated glycoprotein
- MAR:
-
Maternal autoantibody-related autism
- MBP:
-
Myelin basic protein
- MG:
-
Myasthenia gravis
- MOG:
-
Myelin oligodendrocyte glycoprotein
- MS:
-
Multiple sclerosis
- MuSK:
-
Muscle-specific kinase
- MYEOV2:
-
Myeloma overexpressed gene 2
- NMDAR:
-
N-Methyl-D-aspartate glutamate receptor
- NMDARE:
-
NMDAR encephalitis
- NMJ:
-
Neuromuscular junction
- NMO:
-
Neuromyelitis optica
- PCD:
-
Paraneoplastic degeneration
- PEM:
-
Paraneoplastic encephalomyelitis
- PNS:
-
Paraneoplastic neurologic disorder
- PSMD4:
-
Proteasome non-ATPase regulatory subunit 4
- RE:
-
Rasmussen’s encephalitis
- SCI:
-
Spinal cord injury
- SCLC:
-
Small-cell lung cancer
- SGPG:
-
Sulfoglucuronosyl paragloboside
- SLE:
-
Systemic lupus erythematosus
- SPS:
-
Stiff person syndrome
- STIP1:
-
Stress-induced phosphoprotein 1
- SUMPPs:
-
Small myelin protein-derived peptides
- TBI:
-
Traumatic brain injury
- TG:
-
Transglutaminase
- VGCC:
-
Voltage-gated calcium channel
- VGKC:
-
Voltage-gated potassium channel
References
MEDAWAR PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29(1):58–69.
Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res. 1988;472(3):287–324.
Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28(1):5–11.
Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28(1):12–8.
Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001;184(2):101–22.
Cepok S, et al. The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol. 2003;60(6):849–55.
Cepok S, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128(Pt 7):1667–76.
Kuenz B, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One. 2008;3(7):e2559.
Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120(5):1368–79.
Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8(1):3.
Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des. 2005;11(8):973–84.
Coureuil M, et al. Meningococcus Hijacks a β2-adrenoceptor/β-Arrestin pathway to cross brain microvasculature endothelium. Cell. 2010;143(7):1149–60.
Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585(23):3770–80.
Janigro D. Does leakage of the blood-brain barrier mediate epileptogenesis? Epilepsy Curr. 2007;7(4):105–7.
Shlosberg D, et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6(7):393–403.
Schoknecht K, David Y, Heinemann U. The blood-brain barrier-gatekeeper to neuronal homeostasis: clinical implications in the setting of stroke. Semin Cell Dev Biol. 2015;38:35–42.
Alluri H, et al. Blood-brain barrier dysfunction following traumatic brain injury. Metab Brain Dis. 2015;30(5):1093–104.
Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–9.
Knopf PM, et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol. 1998;161(2):692–701.
Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today. 1992;13(12):507–12.
Furneaux HM, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med. 1990;322(26):1844–51.
Eichler TW, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One. 2013;8(6):e66002.
Small M, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018;135(4):569–79.
Ledermann JA, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.
Peterson K, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7.
Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand. 2009;120(1):64–7.
Schubert M, et al. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. 2014;128(6):835–52.
Greenlee JE, et al. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. 2010;69(10):997–1007.
Greenlee JE, et al. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One. 2015;10(4):e0123446.
Hill KE, et al. Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics. J Neuroinflammation. 2009;6:31.
Hida C, et al. Ultrastructural localization of anti-Purkinje cell antibody-binding sites in paraneoplastic cerebellar degeneration. Arch Neurol. 1994;51(6):555–8.
Okano HJ, et al. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev. 1999;13(16):2087–97.
Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol. 2009;155(1):1–15.
Simitsek PD, et al. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med. 1995;181:1957–63.
Riancho J, et al. Herpes simplex encephalitis: clinical presentation, neurological sequelae and new prognostic factors. Ten years of experience. Neurol Sci. 2013;34(10):1879–81.
Armangue T, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014;75(2):317–23.
Gresa-Arribas N, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167–77.
Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65.
Salovin A, et al. Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e458.
Okonkwo DO, et al. GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study. J Neurotrauma. 2013;30(17):1490–7.
Auer LM, Walter GF, Mayer G. Brain edema in acute arterial hypertension III: fluorescence microscopic results. J Neurosurg Sci. 1979;23(4):243–8.
Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42(11):3323–8.
Weller RO, et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117(1):1–14.
Carare RO, Hawkes CA, Weller RO. Afferent and efferent immunological pathways of the brain. Anatomy, function and failure. Brain Behav Immun. 2014;36:9–14.
Arbour RB. Traumatic brain injury: pathophysiology, monitoring, and mechanism-based care. Crit Care Nurs Clin North Am. 2013;25(2):297–319.
Rudehill S, et al. Autoreactive antibodies against neurons and basal lamina found in serum following experimental brain contusion in rats. Acta Neurochir. 2006;148(2):199–205; discussion 205.
Diamond B, et al. Brain-reactive antibodies and disease. Annu Rev Immunol. 2013;31:345–85.
Marchi N, et al. Consequences of repeated blood-brain barrier disruption in football players. PLoS One. 2013;8(3):e56805.
Zhang Z, et al. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One. 2014;9(3):e92698.
Dekaban GA, Thawer S. Pathogenic antibodies are active participants in spinal cord injury. J Clin Invest. 2009;119(10):2881–4.
Ankeny DP, et al. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem. 2006;99(4):1073–87.
Ankeny DP, Guan Z, Popovich PG. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest. 2009;119(10):2990–9.
Xu H, et al. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett. 2008;121(1):1–6.
Scott GN, et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol. 2009;182(12):7509–17.
Lucin KM, et al. Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp Neurol. 2007;207(1):75–84.
Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med. 2009;265(6):663–79.
Iversen PO, et al. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. Blood. 2000;96(6):2081–3.
Riegger T, et al. Spinal cord injury-induced immune depression syndrome (SCI-IDS). Eur J Neurosci. 2007;25(6):1743–7.
Riegger T, et al. Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience. 2009;158(3):1194–9.
Roström B, Link B. Oligoclonal immunoglobulins in cerebrospinal fluid in acute cerebrovascular disease. Neurology. 1981;31(5):590–6.
Prüss H, et al. Evidence of intrathecal immunoglobulin synthesis in stroke: a cohort study. Arch Neurol. 2012;69(6):714–7.
Garty BZ, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.
Saunders NR, Liddelow SA, Dziegielewska KM. Barrier mechanisms in the developing brain. Front Pharmacol. 2012;3:46.
Braniste V, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158.
Vincent A, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet. 1995;346(8966):24–5.
Lee JY, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med. 2009;15(1):91–6.
Warren RP, et al. Detection of maternal antibodies in infantile autism. J Am Acad Child Adolesc Psychiatry. 1990;29(6):873–7.
Atladottir HO, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124(2):687–94.
Braunschweig D, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology. 2008;29(2):226–31.
Cabanlit M, et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci. 2007;1107:92–103.
Zimmerman AW, et al. Maternal antibrain antibodies in autism. Brain Behav Immun. 2007;21(3):351–7.
Braunschweig D, et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry. 2013;3:e277.
Jones KL, et al., Autism-specific maternal autoantibodies produce behavioral abnormalities in an endogenous antigen-driven mouse model of autism. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0126-1
Jones KL, Van de Water J. Maternal autoantibody related autism: mechanisms and pathways. Mol Psychiatry. 2019;24(2):252–65.
Martin LA, et al. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22(6):806–16.
Singer HS, et al. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol. 2006;178(1–2):149–55.
Braunschweig D, et al. Behavioral correlates of maternal antibody status among children with autism. J Autism Dev Disord. 2012;42(7):1435–45.
Piras IS, et al. Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder. Brain Behav Immun. 2014;38:91–9.
Singer HS, et al. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol. 2008;194(1–2):165–72.
Croen LA, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry. 2008;64(7):583–8.
Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. 1999;131(7):522–30.
Raju R, et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol. 2005;175(11):7755–62.
Solimena M, et al. Autoantibodies directed against glutamic acid decarboxylase (GAD) in the cerebrospinal fluid and serum of a patient with Stiff-Man syndrome, epilepsy and type I diabetes mellitus. N Engl J Med. 1988;318:1012–20.
Dinkel K, et al. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. 1998;44(2):194–201.
Dalakas MC, et al. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001;57(5):780–4.
Levy LM, et al. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol. 2005;62(6):970–4.
Hampe CS, et al. Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet J Rare Dis. 2013;8:82.
Manto M, et al. Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. Front Behav Neurosci. 2015;9:78.
Mitoma H, Manto M, Hampe CS. Pathogenic roles of glutamic acid decarboxylase 65 autoantibodies in cerebellar ataxias. J Immunol Res. 2017;2017:2913297.
Kanaani J, et al. A palmitoylation cycle dynamically regulates partitioning of the GABA-synthesizing enzyme GAD65 between ER-Golgi and post-Golgi membranes. J Cell Sci. 2008;121(Pt 4):437–49.
Baekkeskov S, Kanaani J. Palmitoylation cycles and regulation of protein function (Review). Mol Membr Biol. 2009;26(1):42–54.
Manto MU, et al. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis. 2011;6:3.
Hansen N, et al. Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol. 2013;239:202–9.
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–54.
Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–8.
Gilhus NE, et al. Myasthenia gravis – autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–68.
Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5.
Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267–80.
Ruff RL, Lennon VA. How myasthenia gravis alters the safety factor for neuromuscular transmission. J Neuroimmunol. 2008;201–202:13–20.
Jacob A, et al. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007;187(1–2):126–38.
Matiello M, et al. Neuromyelitis optica. Curr Opin Neurol. 2007;20(3):255–60.
Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol. 2011;7(3):115–27.
Jarius S, Wildemann B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link. Med Hypotheses. 2013;81(6):1090–5.
Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.
Waters P, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65(7):913–9.
Frigeri A, et al. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci. 1995;108(Pt 9):2993–3002.
Akman-Demir G, et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol. 2011;258(3):464–70.
Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535–44.
Verkman AS, Anderson MO, Papadopoulos MC. Aquaporins: important but elusive drug targets. Nat Rev Drug Discov. 2014;13(4):259–77.
Melamud L, et al. Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane. J Neurosci Res. 2012;90(6):1240–8.
Nicchia GP, et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia. 2009;57(13):1363–73.
Vincent T, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008;181(8):5730–7.
Ratelade J, et al. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol. 2012;123(6):861–72.
Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012;44(9):1519–30.
Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125(Pt 7):1450–61.
Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol. 2014;255:145–53.
Ratelade J, et al. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013;126(5):699–709.
Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna). 2014;121(8):1029–75.
Wiendl H, et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen’s encephalitis. Neurology. 2001;57(8):1511–4.
Mantegazza R, et al. Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol. 2002;131(1–2):179–85.
Ganor Y, et al. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy. Clin Dev Immunol. 2004;11(3–4):241–52.
Ganor Y, et al. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res. 2005;65(1–2):11–22.
Goldberg-Stern H, et al. Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) associate with some cognitive/psychiatric/behavioral abnormalities in epilepsy patients. Psychoneuroendocrinology. 2014;40:221–31.
Rogers SW, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science. 1994;265(5172):648–51.
Traynelis SF, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–96.
Basile AS, et al. IgG isolated from LP-BM5 infected mouse brain activates ionotropic glutamate receptors. Neurobiol Dis. 2001;8(6):1069–81.
Carlson NG, et al. Identification of amino acids in the glutamate receptor, GluR3, important for antibody-binding and receptor-specific activation. J Biol Chem. 1997;272(17):11295–301.
Twyman RE, et al. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron. 1995;14(4):755–62.
Gahring LC, Rogers SW. Autoimmunity to glutamate receptors in the central nervous system. Crit Rev Immunol. 2002;22(4):295–316.
Fujikawa DG. The role of excitotoxic programmed necrosis in acute brain injury. Comput Struct Biotechnol J. 2015;13:212–21.
Hardingham GE, Bading H. Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim Biophys Acta. 2002;1600(1–2):148–53.
Ganor Y, et al. Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) can be produced in DBA/2J mice, lower seizure threshold and induce abnormal behavior. Psychoneuroendocrinology. 2014;42:106–17.
Howard FM Jr, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526–38.
Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A. 1983;80(13):4089–93.
Drachman DB, et al. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med. 1982;307(13):769–75.
St Pierre CA, et al. Antibodies to cell surface proteins redirect intracellular trafficking pathways. Exp Mol Pathol. 2011;91(3):723–32.
Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 2005;6(10):942–8.
Lee CW, et al. Crosslinking-induced endocytosis of acetylcholine receptors by quantum dots. PLoS One. 2014;9(2):e90187.
Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.
Prüss H, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75(19):1735–9.
Irani SR, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655–67.
Gleichman AJ, et al. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32(32):11082–94.
Hughes EG, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866–75.
Moscato EH, et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;76(1):108–19.
Planagumà J, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94–109.
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–107.
Titulaer MJ, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902–8.
Hajela RK, Huntoon KM, Atchison WD. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels. Muscle Nerve. 2015;51(2):176–84.
Lennon VA, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467–74.
Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989;12(12):496–502.
Meriney SD, et al. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads. Ann N Y Acad Sci. 2018;1412(1):73–81.
Evseev VA, et al. Autoantibodies against glutamate, gamma-aminobutyric acid, and norepinephrine in mechanisms of neuropathic pain syndrome. Bull Exp Biol Med. 2008;145(5):584–7.
Vetrile LA, et al. Immunobiological specificity of antibodies against glutamate and gamma-aminobutyric acid. Bull Exp Biol Med. 2007;143(5):634–7.
Lindstrom J, et al. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci. 1974;274:254–74.
Sanders D, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014;49(4):483–6.
Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol. 2004;61(6):902–4.
Luo J, et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci. 2009;29(44):13898–908.
DB D, et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978;298(20):1116–22.
Engel A, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci. 1987;505:326–32.
Guilliams M, et al. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108.
Doppler K, et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry. 2015;86(7):720–8.
Doppler K, et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain. 2016;139(Pt 10):2617–30.
Appeltshauser L, et al. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins. Exp Neurol. 2017;287(Pt 1):84–90.
Labasque M, et al. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem. 2014;289(11):7907–18.
Abe Y, et al. Masking of the Fc region in human IgG4 by constrained X-ray scattering modelling: implications for antibody function and therapy. Biochem J. 2010;432(1):101–11.
Bruhns P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–25.
Koneczny I. A new classification system for IgG4 autoantibodies. Front Immunol. 2018;12(9):97.
Huijbers M, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110(51):20783–8.
Koneczny I, et al. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One. 2013;8(11):e80695.
Hadjivassiliou M, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Ann Neurol. 2008;64(3):332–43.
Thomas H, et al. Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids. 2013;44(1):161–77.
Mikol D, et al. Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients. J Neuroimmunol. 2006;180(1–2):40–9.
Kelly J. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance. Rev Neurol Dis. 2008;5(1):14–22.
Latov N, Hays A, Sherman W. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988;3(4):301–32.
Nobile-Orazio E, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36(3):416–24.
Pestronk A, et al. Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle Nerve. 2003;27(2):188–95.
Latov N, et al. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci U S A. 1981;78(11):7139–42.
Monaco S, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990;322(10):649–52.
Vital C, et al. Uncompacted myelin lamellae in peripheral nerve biopsy. Ultrastruct Pathol. 2003;27(1):1.
Vallat J, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve. 2003;27(4):478–85.
Tatum A. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993;33(5):502–6.
Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7(6):812–8.
Pirko I, et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 2004;18(13):1577–9.
Miller D, Rodriguez M. Spontaneous and induced remyelination in multiple sclerosis and the Theiler’s virus model of central nervous system demyelination. Microsc Res Tech. 1995;32(3):230–45.
Warrington A, et al. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol. 2004;63(5):461–73.
Warrington A, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A. 2000;97(12):6820–5.
Asakura K, Rodriguez M. A unique population of circulating autoantibodies promotes central nervous system remyelination. Mult Scler. 1998;4(3):217–21.
Fredman P, et al. Monoclonal antibody A2B5 reacts with many gangliosides in neuronal tissue. Arch Biochem Biophys. 1984;233(2):661–6.
Sommer I, Schachner M. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev Biol. 1981;83(2):311–27.
Paz Soldán MM, et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci. 2003;22(1):14–24.
Mitsunaga Y, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 2002;16(10):1325–7.
Watzlawik J, et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia. 2010;58(15):1782–93.
Stein TD, Fedynyshyn JP, Kalil RE. Circulating autoantibodies recognize and bind dying neurons following injury to the brain. J Neuropathol Exp Neurol. 2002;61(12):1100–8.
Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol. 1998;8(9):365–72.
Kay MM, Wyant T, Goodman J. Autoantibodies to band 3 during aging and disease and aging interventions. Ann N Y Acad Sci. 1994;719:419–47.
Denecker G, et al. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett. 2000;465(1):47–52.
van der Neut Kolfschoten M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554–7.
Parissis D, Syntila SA, Ioannidis P. Corticosteroids in neurological disorders: the dark side. J Clin Neurosci. 2017;44:1–5.
Mitoma H, Manto M, Hampe CS. Time is cerebellum. Cerebellum. 2018;17(4):387–91.
Lövblad KO, et al. Autoantibodies in neurological paraneoplastic diseases. Schweiz Arch Neurol Psychiatr (1985). 1994;145(3):3–7.
Honnorat J, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80(4):412–6.
Dalmau J, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain. 1999;122(Pt 1):27–39.
Luque FA, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241–51.
De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178(6):2219–23.
Kyskan R, et al. Antiglycine receptor antibody and encephalomyelitis with rigidity and myoclonus (PERM) related to small cell lung cancer. BMJ Case Rep. 2013;2013.
Newsom-Davis J. Lambert-Eaton myasthenic syndrome: a review. Monogr Allergy. 1988;25:116–24.
Bain PG, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678–83.
Lee JH, et al. A case of lambert-eaton myasthenic syndrome with small-cell lung cancer and transient increase in anti-acetylcholine-receptor-binding antibody titer. J Clin Neurol. 2012;8(4):305–7.
Kornfeld P, et al. Acetylcholine receptor antibodies in myasthenia gravis. Muscle Nerve. 1981;4(5):413–9.
Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci. 2001;88(3):187–92.
Dalmau J, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36.
Bataller L, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology. 2010;74(3):265–7.
Boronat A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795–800.
Milam AH, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34(1):91–100.
Fleisher J, et al. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol. 2013;70(10):1311–4.
Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50(3):301–11.
Matà S, et al. Anti-ganglioside antibodies and elevated CSF IgG levels in Guillain-Barré syndrome. Eur J Neurol. 2006;13(2):153–60.
Terryberry J, et al. Myelin- and microbe-specific antibodies in Guillain-Barré syndrome. J Clin Lab Anal. 1995;9(5):308–19.
Simone IL, et al. Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 1993;114(1):49–55.
Levin MC, et al. Cross-reactivity between immunodominant human T lymphotropic virus type I tax and neurons: implications for molecular mimicry. J Infect Dis. 2002;186(10):1514–7.
Poulet A, et al. Post-malaria neurological syndrome: imported case series and literature review to unscramble the auto-immune hypothesis. Travel Med Infect Dis. 2018.
Kirvan CA, et al. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9(7):914–20.
Kirvan CA, et al. Tubulin is a neuronal target of autoantibodies in Sydenham’s chorea. J Immunol. 2007;178(11):7412–21.
Fujinami RS. Can virus infections trigger autoimmune disease? J Autoimmun. 2001;16(3):229–34.
Olson JK, Croxford JL, Miller SD. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol. 2001;14(3):227–50.
Sigal LH, Tatum AH. Lyme disease patients’ serum contains IgM antibodies to Borrelia burgdorferi that cross-react with neuronal antigens. Neurology. 1988;38(9):1439–42.
Garcia-Monco JC, Coleman JL, Benach JL. Antibodies to myelin basic protein in Lyme disease. J Infect Dis. 1988;158(3):667–8.
Partinen M, et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13(6):600–13.
Saariaho AH, et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun. 2015;63:68–75.
Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun. 2013;43:26–31.
Hische EA, et al. Cerebrospinal fluid IgG and IgM indexes as indicators of active neurosyphilis. Clin Chem. 1988;34(4):665–7.
Levchik N, et al. Criteria for the diagnosis of neurosyphilis in cerebrospinal fluid: relationships with intrathecal immunoglobulin synthesis and blood-cerebrospinal fluid barrier dysfunction. Sex Transm Dis. 2013;40(12):917–22.
Ngankam L, Kazantseva NV, Gerasimova MM. Immunological markers of severity and outcome of traumatic brain injury. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(7):61–5.
Goryunova AV, et al. Glutamate receptor autoantibody concentrations in children with chronic post-traumatic headache. Neurosci Behav Physiol. 2007;37(8):761–4.
Puvenna V, et al. Significance of ubiquitin carboxy-terminal hydrolase L1 elevations in athletes after sub-concussive head hits. PLoS One. 2014;9(5):e96296.
Bazarian JJ, et al. Classification accuracy of serum Apo A-I and S100B for the diagnosis of mild traumatic brain injury and prediction of abnormal initial head computed tomography scan. J Neurotrauma. 2013;30(20):1747–54.
Kiechle K, et al. Subject-specific increases in serum S-100B distinguish sports-related concussion from sports-related exertion. PLoS One. 2014;9(1):e84977.
Sorokina EG, et al. [S100B protein and autoantibodies to S100B protein in diagnostics of brain damage in craniocerebral trauma in children]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(8):30–5.
Davies AL, Hayes KC, Dekaban GA. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil. 2007;88(11):1384–93.
Hayes KC, et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma. 2002;19(6):753–61.
Mizrachi Y, et al. Systemic humoral factors participating in the course of spinal cord injury. Paraplegia. 1983;21(5):287–93.
Skoda D, et al. Antibody formation against beta-tubulin class III in response to brain trauma. Brain Res Bull. 2006;68(4):213–6.
Taranova NP, et al. [The production of autoantibodies to nerve tissue glycolipid antigens in patients with traumatic spinal cord injuries]. Zh Vopr Neirokhir Im N N Burdenko. 1992(4–5):21–4.
Zajarías-Fainsod D, et al. Autoreactivity against myelin basic protein in patients with chronic paraplegia. Eur Spine J. 2012;21(5):964–70.
Hergenroeder GW, et al. Identification of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients. Neuroreport. 2016;27(2):90–3.
Wang R, et al. [Enzyme-linked immunoadsorbent assays for myelin basic protein and antibodies to myelin basic protein in serum and CSF of patients with diseases of the nervous system]. Hua Xi Yi Ke Da Xue Xue Bao. 1995;26(2):131–4.
Palmers I, et al. Antibody profiling identifies novel antigenic targets in spinal cord injury patients. J Neuroinflammation. 2016;13(1):243.
Dambinova SA, et al. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49(10):1752–62.
Weissman JD, et al. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011;300(1–2):97–102.
Ayed K, et al. [Congenital heart block associated with maternal anti SSA/SSB antibodies: a report of four cases]. Pathol Biol (Paris). 2004;52(3):138–47.
Hon KL, Leung AK. Neonatal lupus erythematosus. Autoimmune Dis. 2012;2012:301274.
Buyon JP, Clancy RM. Neonatal lupus syndromes. Curr Opin Rheumatol. 2003;15(5):535–41.
Bitsch A, et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2004;251(12):1498–501.
Gitlits VM, et al. Synapsin I identified as a novel brain-specific autoantigen. J Investig Med. 2001;49(3):276–83.
Maetzler W, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis. 2011;26(1):171–9.
Tsuburaya RS, et al. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis. Brain and Development. 2015;37(1):145–8.
Wang H, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology. 2008;71(15):1142–6.
Baig S, et al. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol. 1991;33(1):73–9.
Sotgiu S, et al. A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: one disease instead of two? BMJ Case Rep. 2009:2009.
Berger T, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349(2):139–45.
Derfuss T, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A. 2009;106(20):8302–7.
Srivastava R, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–23.
Lu XY, et al. Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS One. 2010;5(6):e11124.
Mostafa GA, et al. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol. 2010;227(1–2):195–201.
Mundiyanapurath S, et al. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259(1–2):88–91.
Tsuchiya H, et al. Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(7):1219–28.
Niebroj-Dobosz I, Dziewulska D, Janik P. Auto-antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). Folia Neuropathol. 2006;44(3):191–6.
Tzartos JS, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1(2):80–7.
Offen D, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998;51(4):1100–3.
Yi FH, et al. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J Neuroimmunol. 2000;109(2):211–20.
Pestronk A, et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology. 1988;38(9):1457–61.
Li D, et al. Anti-sulfoglucuronosyl paragloboside antibody: a potential serologic marker of amyotrophic lateral sclerosis. ASN Neuro. 2016;8(5).
Raju R, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain. 2006;129(Pt 12):3270–6.
Geis C, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain. 2010;133(11):3166–80.
Butler MH, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron. 2000;26(2):307–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hampe, C.S. (2019). Significance of Autoantibodies. In: Mitoma, H., Manto, M. (eds) Neuroimmune Diseases. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-030-19515-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-19515-1_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19514-4
Online ISBN: 978-3-030-19515-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)